Top 5 Drug Classes Advertising in Professional Health Journals (Dollars) in Q1 2013

by Client Services

Total print ad dollars spent by advertisers in professional health journals reached $134 MM in the first quarter of 2013, according to Kantar Media. Cancer Therapy Products topped the list with almost $10 million spent and was also the top class by dollars last month. The top product classes by dollars are as follows:

Top 5 Print Ad Drug Classes (Dollars): Jan. – Mar. 2013

#1 Cancer Therapy Products – $10 MM (+7%)

#2 Anticoagulants Oral – $7 MM (+13%)

#3 Steroids, Inhaled Bronch – $4 MM (N/A)

#4 Irritant Stimulant Laxatives – $4 MM (N/A)

#5 Diabetes Insulin – $3 MM (-36%)

Zytiga, a cancer therapy product, appeared in the top five products in the first quarter with about $1 million spent advertising in professional health journals.

The percentage changes compare Q1 2013 to Q1 2012. For more information on these ad insights or other data, let one of us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.